RECORDATI |
Market Closed -
Other stock markets
|
After market 12:45:33 pm | |||
| 52.6 EUR | +2.94% |
|
52.65 | +0.10% |
| 06:02pm | Mib rises; A2A on fifth bullish session in a row. | AN |
| 11:56am | Mib above 34,000 threshold; TIM among the best | AN |
| Sales 2024 * | 2.3B 2.46B | Sales 2025 * | 2.44B 2.61B | Capitalization | 10.52B 11.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 482M 516M | Net income 2025 * | 527M 564M | EV / Sales 2024 * | 5.14 x |
| Net Debt 2024 * | 1.3B 1.39B | Net Debt 2025 * | 1.07B 1.14B | EV / Sales 2025 * | 4.76 x |
| P/E ratio 2024 * |
22.7
x | P/E ratio 2025 * |
20.3
x | Employees | 4,455 |
| Yield 2024 * |
2.77% | Yield 2025 * |
3.06% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
| 1 day | +2.94% | ||
| 1 week | +6.61% | ||
| Current month | +2.65% | ||
| 1 month | +1.15% | ||
| 3 months | +5.79% | ||
| 6 months | +19.46% | ||
| Current year | +7.72% |
1 week
48.62
52.95
1 month
48.5452.95
Current year
47.2953.38
1 year
40.0053.38
3 years
34.5257.90
5 years
28.2657.90
10 years
11.1257.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 50 | 18-06-11 |
Giampiero Mazza
BRD | Director/Board Member | 54 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 52.6 | +2.94% | 390 244 |
| 24-04-22 | 51.1 | +2.49% | 474,728 |
| 24-04-19 | 49.86 | +0.24% | 252,235 |
| 24-04-18 | 49.74 | +1.63% | 226,309 |
| 24-04-17 | 48.94 | -0.81% | 217,036 |
Real-time Borsa Italiana, April 23, 2024 at 11:44 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
51.1
EUR
Average target price
51.24
EUR
Spread / Average Target
+0.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.72% | 11.19B | |
| +27.55% | 659B | |
| +27.68% | 557B | |
| -4.23% | 359B | |
| +16.60% | 322B | |
| +9.78% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.82% | 149B |
- Stock Market
- Equities
- REC Stock
